Dr Holubar, from the Cleveland Clinic, discusses his research into the question of whether patients who take biologic therapies prior to surgery for IBD are more likely to develop postoperative complications.
Dr Cohen, director of the IBD Center at the University of Chicago, recaps his presentation at the Crohn's & Colitis Congress 2021 on using novel small molecule agents to treat inflammatory bowel disease.
In this video, Dr Hanauer, from the Feinberg School of Medicine at Northwestern University in Chicago, reviews his presentation at the Crohn's & Colitis Congress 2021 on "evolutionary" agents on the horizon for treatment of inflammatory bowel disease.
In this video, Dr Abreu, director of the Crohn's and Colitis Center at the University of Miami Miller School of Medicine, previews her talk for the Crohn's & Colitis Congress 2021 on how basic research is being translated to advances in direct care for patients with inflammatory bowel disease.
Dr Brenner discusses her presentation at the Crohn's & Colitis Congress on what data indicate about the risks and disease course of pediatric patients with inflammatory bowel disease during the COVID-19 pandemic.
In this commentary, Laurie Keefer, PhD, AGAF, from the Icahn School of Medicine at Mount Sinai in New York, challenges gastroenterologists to take a more holistic view of their patients with inflammatory bowel disease, and to look beyond clinical signs and symptoms to the question of whether the patient is living well, in her address to the Crohn's & Colitis Congress 2021.

Dr Cohen reviews his presentation from the Crohn's & Colitis Congress 2021 about positioning novel small molecule therapies, including JAK inhibitors, in the treatmen